William E Carson, III MD

William E Carson, III MD
ProfessorCollege of Medicinecarson.77@osu.eduwebsite
N911 Doan Hall 410 W 10th Avenue Columbus Ohio 43210
Phone:614-293-6306Fax: 614-293-3465
  • Innate Immunity

General Research Interest

Tumor immunology

Research Description

Dr. Carson is a surgical oncologist with clinical interests in breast cancer, melanoma and general cancer surgery. His primary research focus is the immunotherapy of tumors, which can be thought of as using drugs and other treatments to boost the human immune system's innate ability to fight tumor cells. Dr. Carson came to Ohio State in 1997 from Roswell Park Cancer Institute in Buffalo. NY. He is a professor of surgery and of Medical Microbiology and Immunology. In addition to his role as Associate Director for Clinical Research in the OSU Comprehensive Cancer Center (OSUCCC), he serves as co-leader of the OSUCCC Immunology Program. He has a number of active cancer research grants which look at novel immunological approaches to the treatment of advanced malignant melanoma, the most deadly form of skin cancer.

Transinstitutional Work

Dr. Carson collaborates with OSU investigators who are investigating the effects of stress on immunity, nanotechnology for caner therapy, and the personalized use experimental therapeutics. He is active in the Society for Immunotherapy of Cancer and serves on the NCCN (National Comprehensive Cancer Network) advisory board for Melanoma. Dr. Carson is currently Vice Chair of the SWOG Melanoma Committee and he is on the NCCN Board of Directors. He also serves on the NCI IRG Subcommittee A that oversees the certification of Cancer Centers in the United States.

Current Publications

  • de la Chapelle AIntronic miR-3151 Within BAALC Drives Leukemogenesis by Deregulating the TP53 Pathway.Sci Signal 7 ra36 4/15/2014
  • Kiecolt-Glaser JKCognitive problems among breast cancer survivors: loneliness enhances risk.Psychooncology 4/11/2014
  • Carson WE 3rdSignaling pathways involved in MDSC regulation.Biochim Biophys Acta 4/10/2014
  • Kiecolt-Glaser JKSocial support predicts inflammation, pain, and depressive symptoms: Longitudinal relationships among breast cancer survivors.Psychoneuroendocrinology 42 38-44 4/1/2014
  • Olencki TA phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.J Immunother 37 180-6 4/1/2014
  • de la Chapelle ANRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.Proc Natl Acad Sci U S A 111 4179-84 3/18/2014
  • Carson WE 3rdA Phase I Trial of Bortezomib and Interferon-a-2b in Metastatic Melanoma.J Immunother 37 55-62 1/1/2014
  • Gray MR, Martin Del Campo S, Zhang X, Zhang H, Souza FF, Carson WE 3rd, Smith ADMetastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab.Radiology in press 9/26/2013
  • Jaremka LM, Andridge RR, Fagundes CP, Alfano CM, Povoski SP, Lipari AM, Agnese DM, Arnold MW, Farrar WB, Yee LD, Carson WE, Bekaii-Saab T, Martin EW, Schmidt CR, Kiecolt-Glaser JKPain, Depression, and Fatigue: Loneliness as a Longitudinal Risk Factor.Health Psychol in press 8/19/2013
  • Liu Z, Yu J, Carson WE 3rd, Bai XFThe role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response.Am J Transl Res 5(5) 470-80 8/15/2013
  • Lindgren ME, Fagundes CP, Alfano CM, Povoski SP, Agnese DM, Arnold MW, Farrar WB, Yee LD, Carson WE, Schmidt CR, Kiecolt-Glaser JKBeta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients.Psychooncology 22(8) 1889-94 8/1/2013
  • Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE 3rdMyeloid-derived suppressor cells in breast cancer.Breast Cancer Res Treat 140(1) 13-21 7/1/2013
  • Matthews MA, Watkins D, Darbyshire A, Carson WE, Besner GEHeparin-binding EGF-like growth factor (HB-EGF) protects the intestines from radiation therapy-induced intestinal injury.J Pediatr Surg 48(6) 1316-22 6/1/2013
  • Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho MMelanoma, version 2.2013: featured updates to the NCCN guidelines.J Natl Compr Canc Netw 11(4) 395-407 4/1/2013
  • Foy KC, Miller MJ, Moldovan N, Carson WE, Kaumaya PPCorrection to: Foy KC, Miller MJ, Moldovan N, Carson III WE, Kaumaya PTP. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 201Oncoimmunology 2(1) e23914 1/1/2013
  • Markowitz J, Carson WE 3rdReview of S100A9 biology and its role in cancer.Biochim Biophys Acta 1835(1) 100-9 1/1/2013
  • Khrizman P, Niland JC, Ter Veer A, Milne D, Bullard Dunn K, Carson WE 3rd, Engstrom PF, Shibata S, Skibber JM, Weiser MR, Schrag D, Benson AB 3rdPostoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis.J Clin Oncol 31(1) 30-8 1/1/2013
  • Tarr AJ, Powell ND, Reader BF, Bhave NS, Roloson AL, Carson WE 3rd, Sheridan JFβ-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption.Brain Behav Immun 26(8) 1226-38 11/1/2012
  • Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson Iii WE, Kaumaya PTImmunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer.Oncoimmunology 1(7) 1004-1016 10/1/2012
  • Foy KC, Miller MJ, Moldovan N, Carson Iii WE, Kaumaya PTCombined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.Oncoimmunology 1(7) 1048-1060 10/1/2012
  • Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Carson WE 3rdCetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.Surgery 152(3) 431-40 9/1/2012
  • Abdel-Rahman MH, Cebulla CM, Verma V, Christopher BN, Carson WE 3rd, Olencki T, Davidorf FHMonosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival.Exp Eye Res 100 26-31 7/1/2012
  • Luedke E, Cristina Jaime-Ramirez A, Bhave N, Carson WE 3rdMonoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.J Immunother 35(5) 367-73 6/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu